Entries by CAPTIS

Jazz Pharmaceuticals receives EU marketing authorisation for Sunosi for excessive daytime sleepiness in adults with narcolepsy or OSA

Sunosi is the first dual-acting dopamine and norepinephrine reuptake inhibitor approved to treat EDS in adults living with narcolepsy or OSA and the only licensed therapy in the The post Jazz Pharmaceuticals receives EU marketing authorisation for Sunosi for excessive daytime sleepiness in adults with narcolepsy or OSA appeared first on Pharmaceutical Business review.

Innovation Pharmaceuticals announces dose escalation

Safety findings from the first cohort were reviewed by the DEC. The Principal Medical Investigator and Sponsor agreed it acceptable to increase the dose of Brilacidin for administration The post Innovation Pharmaceuticals announces dose escalation appeared first on Pharmaceutical Business review.

Verrica Pharmaceuticals announces presentation of positive data from new pooled analysis of phase 3 CAMP trials of VP-102

The new analysis showed that the percentage of patients with complete clearance of all lesions was statistically significantly higher in the VP-102 group than vehicle, across all body The post Verrica Pharmaceuticals announces presentation of positive data from new pooled analysis of phase 3 CAMP trials of VP-102 appeared first on Pharmaceutical Business review.

Civica Rx partners with Thermo Fisher Scientific to develop and manufacture drugs with a history of drug shortages

By working with Thermo Fisher to develop Civica-owned Abbreviated New Drug Applications (ANDAs), Civica will secure the manufacture of certain essential medications, further mitigating the risk of drug The post Civica Rx partners with Thermo Fisher Scientific to develop and manufacture drugs with a history of drug shortages appeared first on Pharmaceutical Business review.